Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 8:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Hypertrophic Clear all

Conditions: Congenital Heart Defect
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 9,999,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Sinusitis, Nasal Obstruction, Turbinate; Hypertrophy Mucous Membrane, Deviated Nasal Septum - Congenital, Deviated Nasal Septum Acquired
Interventions: Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML); Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Hypertrophic Cardiomyopathy, Genetic Disease, Gene Product Sequence Variation
Interventions: Genomic sequencing; Genetic
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertrophic Scarring
Interventions: Silicone Only Therapy (SOT), Silicone Pressure Garment Therapy (SPGT); Procedure
Lead sponsor: Seton Healthcare Family; Other
Eligibility: 1 Year to 18 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Left Ventricular Hypertrophy
Interventions: Customized discharge and expedited referral instructions; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions: Aficamten (5 - 20 mg); Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 57
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 43 more

Conditions: Hypertrophic Cardiomyopathy
Interventions: MYK-461; Drug
Lead sponsor: MyoKardia, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 7
States / cities: Scottsdale, Arizona • Cypress, California • Stanford, California + 4 more

Conditions: Healthy, Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 195 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery
Interventions: PF-06473871; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 57 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Coral Gables, Florida • Miami, Florida • Atlanta, Georgia + 1 more

Conditions: Cardiovascular Disease
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 13 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Tenafly, New Jersey

Conditions: Hypertrophy, Left Ventricular, Hypertension, Cardiomyopathies
Interventions: Intervention: Population Health Coordinator; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 75 Years
Enrollment: 648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Hypertension
Interventions: Diagnostic imaging procedures.; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Heart Failure With Preserved Ejection Fraction, Pulmonary Disease, Left Ventricular Hypertrophy/Hypertension
Interventions: Dobutamine, Amlodipine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hypertrophy
Interventions: Resistance Exercise, Whole Eggs, Egg Whites; Behavioral · Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Myocardial Infarction, Angina, Unstable, Cardiomyopathy, Hypertrophic
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiomyopathy, Hypertrophic Obstructive
Interventions: BHB-1893, Metoprolol; Drug
Lead sponsor: Braveheart Bio, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Manhasset, New York • Rock Hill, South Carolina • Plano, Texas

Conditions: Healthy Participants
Interventions: Mavacamten; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 158 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 4
States / cities: Miami, Florida • Springfield, Missouri • Austin, Texas

Conditions: Hypertension, Left Ventricular Hypertrophy, Overweight
Interventions: Aliskiren 150/300 mg, Losartan 50/100 mg, Aliskiren placebo, Losartan 50/100 mg placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Acne Scars - Mixed Atrophic and Hypertrophic, Hyperpigmentation, Laser-Induced Hyperpigmentation
Interventions: Sciton Halo; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Elmsford, New York

Conditions: Cardiomyopathy, Hypertrophic, Heart Hypertrophy
Interventions: Cyclosporine A; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiomyopathy, Hypertrophic, Familial
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 9,999 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tonsillar Hypertrophy, Adenoid Hypertrophy, Cryptorchidism, Hypospadias, Hydrocele
Interventions: Interactive Perioperative Teaching Platform; Other
Lead sponsor: Vidya Raman; Other
Eligibility: Up to 18 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Keloid
Interventions: Not listed
Lead sponsor: Tirgan, Michael H., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Non-obstructive Hypertrophic Cardiomyopathy
Interventions: mavacamten, Placebo; Drug
Lead sponsor: MyoKardia, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 32
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 28 more

Search by objective public record fields.

Signs and Symptoms Associated With Molecular Defects in Genetically Inherited Heart Disease

Effect of Tranexamic Acid on Postoperative Bleeding Following Sinus and Nasal Surgery

Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy

A Randomized Control Trial for Preventative Scar Management

Point-of-care Ultrasound and Treatment Disparities for Left Ventricular Hypertrophy

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461

Investigation Into the Use of Ultrasound Technique in the Evaluation of Heart Disease

A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study

The Perceived Impact of Children s Risk Status for Hypertrophic Cardiomyopathy on Families: an Exploratory Study

Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy

Right Ventricular Hypertrophy and Pulmonary Hypertension: A Correlation Analysis

Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)

Muscle Protein Synthesis After Whole Egg vs. Egg White Consumption

Using Magnetic Resonance Imaging to Evaluate Heart Vessel Function After Angioplasty or Stent Placement Procedures

BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy

A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy Participants

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension

Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color

Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)

Signs and Symptoms of Genetic Abnormalities Linked to Inherited Heart Disease

Interactive Perioperative Teaching Platform (IPTP)

Web Based Investigation of Natural History of Keloid Disorder, an Online Survey

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)